Marieke van Leeuwen

Marieke van Leeuwen

Auto-generated profile, based on publicly available information

Marieke van Leeuwen

Division of Psychosocial Research & Epidemiology The Netherlands Cancer Institute Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
JGJohannes M. Giesinger
Johannes M. Giesinger
FLFanny L.C. Loth
Fanny L.C. Loth
NANeil K. Aaronson
Neil K. Aaronson
JAJuan I. Arraras
Juan I. Arraras
GCGiovanni Caocci
Giovanni Caocci
BHBernhard Holzner
Bernhard Holzner
The objective of this study was to establish thresholds for clinical importance (TCIs) for the five functioning and nine symptom scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). In this diagnostic study, cancer patients with mixed diagnoses and treatments completed the EORTC QLQ-C30 and anchored the questions in each domain in terms of their clinical importance. The anchor questions, concerned limitations in daily life, need for help/care, and the worries of the patient and his/her partner/family. These questions allowed categorizing patients into whether they exhibited a clinically important symptom/functional impairment for each scale and performing a receiver operating characteristic curve analysis to establish TCIs. Data from 498 patients from six European countries (mean age 60.4 years, 55.2% women) were analyzed. For the TCIs generated using the patient questionnaire data, the EORTC QLQ-C30 scales showed sensitivity values between 0.71 and 0.97 and specificity values between 0.62 and 0.92 (area under the curve above 0.80 for all scales). This EORTC Quality of Life Group study provides TCIs for the functioning and symptom scales of the EORTC QLQ-C30. These TCIs can increase the interpretability of the questionnaire results and foster its use in daily clinical practice and in clinical research.

1 April 2009 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
JPJiska S. Peper
Jiska S. Peper
RBRachel M. Brouwer
Rachel M. Brouwer
HSHugo G. Schnack
Hugo G. Schnack
GBG. Caroline van Baal
G. Caroline van Baal
MLMarieke van Leeuwen
Marieke van Leeuwen
HPHilleke E. Hulshoff Pol
Hilleke E. Hulshoff Pol

4 June 2018 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
MLMarieke Van Leeuwen
Marieke Van Leeuwen
Olga HussonOlga Husson
Olga Husson
PAOLA ALBERTIPAOLA ALBERTI
PAOLA ALBERTI
JAJuan Ignacio Arraras
Juan Ignacio Arraras
OCOlivier L. Chinot
Olivier L. Chinot
LPLonneke V. Van De Poll-Franse
Lonneke V. Van De Poll-Franse
The number of cancer survivors is growing steadily and increasingly, clinical trials are being designed to include long-term follow-up to assess not only survival, but also late effects and health-related quality of life (HRQOL). Therefore it is is essential to develop patient-reported outcome measures (PROMs) that capture the full range of issues relevant to disease-free cancer survivors. The objectives of this project are: 1) to develop a European Organisation for Research and Treatment of Cancer (EORTC) questionnaire that captures the full range of physical, mental and social HRQOL issues relevant to disease-free cancer survivors; and 2) to determine at which minimal time since completion of treatment the questionnaire should be used. We reviewed 134 publications on cancer survivorship and interviewed 117 disease-free cancer survivors with 11 different types of cancer across 14 countries in Europe to generate an exhaustive, provisional list of HRQOL issues relevant to cancer survivors. The resulting issue list, the EORTC core questionnaire (QLQ-C30), and site-specific questionnaire modules were completed by a second group of 458 survivors. We identified 116 generic survivorship issues. These issues covered body image, cognitive functioning, health behaviors, negative and positive outlook, health distress, mental health, fatigue, sleep problems, physical functioning, pain, several physical symptoms, social functioning, and sexual problems. Patients rated most of the acute symptoms of cancer and its treatment (e.g. nausea) as no longer relevant approximately one year after completion of treatment. Compared to existing cancer survivorship questionnaires, our findings underscore the relevance of assessing issues related to chronic physical side effects of treatment such as neuropathy and joint pain. We will further develop a core survivorship questionnaire and three site-specific modules for disease-free adult cancer survivors who are at least one year post-treatment.

17 March 2009 in Human Brain Mapping
Verified
Journal Article
Closed access
JPJiska S. Peper
Jiska S. Peper
HSHugo G. Schnack
Hugo G. Schnack
RBRachel M. Brouwer
Rachel M. Brouwer
GBG. Caroline M. Van Baal
G. Caroline M. Van Baal
EPEneda Pjetri
Eneda Pjetri
HPHilleke E. Hulshoff Pol
Hilleke E. Hulshoff Pol

1 April 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VAVera Atema
Vera Atema
MLMarieke van Leeuwen
Marieke van Leeuwen
JKJacobien M. Kieffer
Jacobien M. Kieffer
HOHester S.A. Oldenburg
Hester S.A. Oldenburg
MBMarc van Beurden
Marc van Beurden
NANeil K. Aaronson
Neil K. Aaronson
PURPOSE: We evaluated the effect of Internet-based cognitive behavioral therapy (iCBT), with or without therapist support, on the perceived impact of hot flushes and night sweats (HF/NS) and overall levels of menopausal symptoms (primary outcomes), sleep quality, HF/NS frequency, sexual functioning, psychological distress, and health-related quality of life in breast cancer survivors with treatment-induced menopausal symptoms. PATIENTS AND METHODS: We randomly assigned 254 breast cancer survivors to a therapist-guided or a self-managed iCBT group or to a waiting list control group. The 6-week iCBT program included psycho-education, behavior monitoring, and cognitive restructuring. Questionnaires were administered at baseline and at 10 weeks and 24 weeks postrandomization. We used mixed-effects models to compare the intervention groups with the control group over time. Significance was set at P < .01. An effect size (ES) of .20 was considered small, .50 moderate and clinically significant, and .80 large. RESULTS: Compared with the control group, the guided and self-managed iCBT groups reported a significant decrease in the perceived impact of HF/NS (ES, .63 and .56, respectively; both P < .001) and improvement in sleep quality (ES, .57 and .41; both P < .001). The guided group also reported significant improvement in overall levels of menopausal symptoms (ES, .33; P = .003), and NS frequency (ES, .64; P < .001). At longer-term follow-up (24 weeks), the effects remained significant, with a smaller ES for the guided group on perceived impact of HF/NS and sleep quality and for the self-managed group on overall levels of menopausal symptoms. Additional longer-term effects for both intervention groups were found for hot flush frequency. CONCLUSION: iCBT, with or without therapist support, has clinically significant, salutary effects on the perceived impact and frequency of HF/NS, overall levels of menopausal symptoms, and sleep quality.

1 August 2008 in Psychoneuroendocrinology
Verified
Journal Article
Closed access
JPJiska S. Peper
Jiska S. Peper
RBRachel M. Brouwer
Rachel M. Brouwer
HSHugo G. Schnack
Hugo G. Schnack
GBG. Caroline M. van Baal
G. Caroline M. van Baal
MLMarieke van Leeuwen
Marieke van Leeuwen
HPHilleke E. Hulshoff Pol
Hilleke E. Hulshoff Pol